Storia in 5 fonti

FDA Expands Approval of Chemo-Free Bladder Cancer Combo in Curative Setting

Perioperative Keytruda-Padcev for MIBC approved regardless of cisplatin eligibility

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo15 h fa

FDA Expands Approval of Chemo-Free Bladder Cancer Combo in Curative Setting

Perioperative Keytruda-Padcev for MIBC approved regardless of cisplatin eligibility

originale

morningstar.com

Timeline cronologica

venerdì 10 luglio 2026·healio.com
Pembrolizumab regimens snag FDA nod for muscle-invasive bladder cancer
The FDA has approved two immunotherapy combination therapies for adults with muscle-invasive bladder cancer. Pembrolizumab (Keytruda, Merck) or pembrolizumab and…
venerdì 10 luglio 2026·medpagetoday.com
FDA Expands Approval of Chemo-Free Bladder Cancer Combo in Curative Setting
Perioperative Keytruda-Padcev for MIBC approved regardless of cisplatin eligibility

10 h fa

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph),…

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With…

Leggi questa versione → originale

healio.com1 g fa

Pembrolizumab regimens snag FDA nod for muscle-invasive bladder cancer

The FDA has approved two immunotherapy combination therapies for adults with muscle-invasive bladder cancer. Pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck)…

Leggi questa versione → originale

benzinga.com10 h fa

Pfizer, Astellas Expand PADCEV-Keytruda Label With FDA Nod In Bladder Cancer - Pfizer (NYSE:PFE)

FDA approves Pfizer and Astellas' PADCEV plus Keytruda for muscle-invasive bladder cancer, backed by Phase 3 survival data.

Leggi questa versione → originale

fiercepharma.com11 h fa

Star Padcev-Keytruda combo expands bladder cancer reach with FDA approval, pressuring AstraZeneca

The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The forever more popular combination of Padcev and Keytruda has expanded its bladder cancer…

Leggi questa versione → originale

venerdì 10 luglio 2026·

morningstar.com

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin…

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

venerdì 10 luglio 2026·

fiercepharma.com

Star Padcev-Keytruda combo expands bladder cancer reach with FDA approval, pressuring AstraZeneca

The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The forever more popular combination of Padcev and…

venerdì 10 luglio 2026·

benzinga.com

Pfizer, Astellas Expand PADCEV-Keytruda Label With FDA Nod In Bladder Cancer - Pfizer (NYSE:PFE)

FDA approves Pfizer and Astellas' PADCEV plus Keytruda for muscle-invasive bladder cancer, backed by Phase 3 survival data.

venerdì 10 luglio 2026·

morningstar.com

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab…

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and…